Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A single-site, phase 1, double-blind, safety and immunogenicity trial of an alphavirus replicon vaccine expressing cytomegalovirus genes (AVX601) in healthy volunteers

Next Previous
Trial Profile

A single-site, phase 1, double-blind, safety and immunogenicity trial of an alphavirus replicon vaccine expressing cytomegalovirus genes (AVX601) in healthy volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 14 Nov 2008

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AVX 601 (Primary) ; AVX 601 (Primary)
  • Indications Cytomegalic inclusion disorders; Cytomegalovirus infections
  • Focus Adverse reactions
  • Sponsors AlphaVax

Most Recent Events

  • 07 Nov 2008 Status changed from active, no longer recruiting to completed, based on information from ClinicalTrials.gov.
  • 25 Oct 2008 Interim results presented at ICAAC/IDSA 2008.
  • 17 Apr 2008 Preliminary results reported in an AlphaVax media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top